- Home
- TLSI vs PIM Comparison
TLSI vs PIM Comparison
Compare TLSI & PIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- PIM
- Stock Information
- Founded
- TLSI 2010
- PIM 1988
- Country
- TLSI United States
- PIM United States
- Employees
- TLSI N/A
- PIM N/A
- Industry
- TLSI Medical Specialities
- PIM Finance Companies
- Sector
- TLSI Health Care
- PIM Finance
- Exchange
- TLSI Nasdaq
- PIM Nasdaq
- Market Cap
- TLSI 124.9M
- PIM 157.1M
- IPO Year
- TLSI N/A
- PIM N/A
- Fundamental
- Price
- TLSI $4.69
- PIM $3.26
- Analyst Decision
- TLSI Strong Buy
- PIM
- Analyst Count
- TLSI 6
- PIM 0
- Target Price
- TLSI $11.75
- PIM N/A
- AVG Volume (30 Days)
- TLSI 36.4K
- PIM 57.5K
- Earning Date
- TLSI 11-14-2024
- PIM 01-01-0001
- Dividend Yield
- TLSI N/A
- PIM 8.28%
- EPS Growth
- TLSI N/A
- PIM N/A
- EPS
- TLSI N/A
- PIM 0.05
- Revenue
- TLSI $26,891,000.00
- PIM N/A
- Revenue This Year
- TLSI $60.96
- PIM N/A
- Revenue Next Year
- TLSI $53.65
- PIM N/A
- P/E Ratio
- TLSI N/A
- PIM $63.80
- Revenue Growth
- TLSI 67.90
- PIM N/A
- 52 Week Low
- TLSI $3.50
- PIM $2.90
- 52 Week High
- TLSI $10.42
- PIM $3.28
- Technical
- Relative Strength Index (RSI)
- TLSI 51.68
- PIM 48.03
- Support Level
- TLSI $4.72
- PIM $3.21
- Resistance Level
- TLSI $5.32
- PIM $3.28
- Average True Range (ATR)
- TLSI 0.31
- PIM 0.05
- MACD
- TLSI 0.01
- PIM -0.00
- Stochastic Oscillator
- TLSI 47.52
- PIM 68.75
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.